1-UFT protocol
1-UFT protocol Basic information
- Product Name:
- 1-UFT protocol
- Synonyms:
-
- 1-UFT protocol
- Tegafur uracil
- Tegafur/Uracil
- Tegafur·uracil
- Tegafur-Uracil
- UFT
- UFT-E
- BMS-200604
- CAS:
- 74578-38-4
- MF:
- C12H13FN4O5
- MW:
- 312.2538232
- Mol File:
- 74578-38-4.mol
1-UFT protocol Chemical Properties
- form
- Solid
- color
- White to off-white
1-UFT protocol Usage And Synthesis
Uses
Tegafur-Uracil (UFT; BMS-200604) is an effective oral chemotherapy drug based on fluoropyrimidine. Tegafur-Uracil inhibits thymidylate synthase. Tegafur-Uracil can be used in combination with leucovorin (LV) and polysaccharide K (PSK) for research on solid tumors[1][2].
in vivo
Tegafur-Uracil (60 mg/kg, orally, once a day for 9 days) combined with folinic acid and protein-bound polysaccharides enhances the anti-tumor activity in mice[2].
| Animal Model: | BLAB/c mice[2] |
| Dosage: | 60 mg/kg; daily; 9 days |
| Administration: | Oral |
| Result: | Reduced tumor size. |
References
[1] Casado E, et al. UFT (tegafur-uracil) in rectal cancer. Ann Oncol. 2008;19(8):1371-1378. DOI:10.1093/annonc/mdn067
[2] Ryoji Katoh, et al. Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Cell Mol Immunol. 2007 Aug;4(4):295-9. PMID:17764620